The anti-tumor effects of CD19 targeting CAR-T cells have been extensively explored and reported in patients with B-cell acute lymphocytic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (non-NHL), and other CD19 positive cancers [8]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.